ArticleCancer medicine2025
Leveraging Artificial Intelligence and Radiomics for Improved Nasopharyngeal Carcinoma Prognostication.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Emerging applications of artificial intelligence for risk stratification in head and neck cancer: a scoping review.Frontiers in oncology · 2026Pooled it
- Deep learning-radiomics-SUVmax integration fromFrontiers in oncology · 2026Article
- Prediction of local recurrence in cohorts of head and neck cancer patients after intensity-modulated radiation therapy based on CT radiomics: A double-center observation study.Translational oncology · 2026Article
- Exploring the prognostic value of EBV DNA in advanced nasopharyngeal carcinoma treated with chemoradiotherapy using AI-based modeling.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNasopharyngeal carcinoma (NPC) typically presents as advanced disease due to the lack of significant symptoms in the early stages. Accurate prognostication is therefore challenging as current methods based on anatomical staging often lack the granularity to differentiate between patients with differing prognoses. This study investigates the potential of radiomics to improve the prediction of locoregional recurrence (LRR) and overall survival in patients with NPC.
methodsRadiomic features were extracted from radiotherapy planning CT scans for 294 NPC patients divided into training (n = 147) and validation (n = 147) sets. A feature selection step utilising feature clustering and mutual information classifier to select six key radiomic features was employed to reduce redundancy and improve interpretability. Models were trained using clinical data, radiomic features, and these in combination to predict 2-year LRR, with performance assessed on the left-out independent validation set.
resultsCombining radiomic features with clinical data resulted in the best performance for predicting 2-year LRR (Area Under the Curve, AUC 0.76) compared to prediction using clinical or radiomic features alone (mean AUC 0.56 and 0.57, respectively). Risk stratification based on the combined model was significant for LRR-free survival and overall survival (p < 0.01). Key radiomic features included tumour size, intensity distribution, overall textural patterns, and distribution of fine and coarse textured regions. DISCUSSION: Radiomics holds promise for improving NPC risk stratification, potentially allowing for personalised treatment strategies. The most important radiomics feature, maximum 2D diameter, suggests a need to reconsider tumour size as a prognostic criterion despite its current exclusion from TNM staging. Larger prospective studies are needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.